• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • QED-C
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Biomedical sciences publications August 1, 2014 Conference Paper

Synthesis of Doxycycline-[(CD3)-C-13]

Citation

Copy to clipboard


Bordia, T., McGregor, M., Papke, R. L., McIntosh, M. J., Decker, M. W., & Quik, M. (2014, 15-19 November). The ?7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in parkinsonian rats. Paper presented at Neuroscience 2014, Washington, DC.

Abstract

Doxycycline is a tetracycline antibiotic that is used to treat a wide variety of infections. A mass spectrometry (MS) analytical standard with M + 4 was prepared to support pharmacology and toxicology. Our approach was to first N-demethylate doxycycline and re-methylate using stable isotope labeled methyl-[13CD3] iodide to produce doxycycline-[13CD3]. An iron mediated Polonovsky reaction efficiently N-demethylated doxycycline. In this process, doxcycline was oxidized to the N-oxide using m-CPBA. The hydrochloride salt of the tertiary N-oxide was treated with Fe(0)/FeCl3 catalyst yielding the N-demethylated product. Isolated pure demethyldoxycycline was re-methylated using diisopropyl azodicarboxylate (DIAD), polymer-supported triphenylphosphine and methyl-[13CD3] iodide. We have synthesized labeled doxycycline with an isotopic purity of 99% using this methodology.

↓ View online

Share this

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2022 SRI International